Balaxi Pharmaceuticals Limited has responded to the National Stock Exchange (NSE) regarding a significant movement in its equity share price. The company stated that there is no material information or announcement that could be influencing the price or volume behavior of its scrip. Balaxi Pharmaceuticals clarified that the price movement is purely market-driven. The company affirmed its adherence to all provisions of Regulation 30 of the SEBI (LODR) Regulations, 2015, and assured the exchange that it will continue to comply with all future information disclosure requirements. This clarification was issued in response to an NSE letter dated 08th April, 2026, concerning the recent price fluctuations of Balaxi Pharmaceuticals' shares.
